We are advising Coloplast on the transaction

Davis Polk is advising Coloplast A/S on its acquisition of the outstanding shares of Uromedica, Inc., which will become a wholly owned subsidiary of Coloplast. Financial terms of the transaction were not disclosed.

Coloplast develops products and services to make life easier for people with deeply personal and private medical conditions. Coloplast’s business includes ostomy care, continence care, advanced wound care, interventional urology, and voice and respiratory care. Coloplast is headquartered in Denmark and operates globally, employing more than 16,500 people.

Uromedica is a Minnesota-based medical device company that has developed long-term implantable balloon therapies for male and female stress urinary incontinence. Uromedica has safe and effective products that have been implanted in over 16,000 patients worldwide with excellent results.

The Davis Polk corporate team includes partner Harold Birnbaum and associates Rahul Srivastava and Adam Pukier. Partner David R. Bauer and associate Emma Willems are providing intellectual property advice. Partner Veronica M. Wissel and associate Chloe (Tianyi) Wang are providing executive compensation advice. Partner William A. Curran and associate Seth Cole are providing tax advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post